Table 1.
Patient characteristics at baseline
| Characteristic | Total (N = 167) | Methylated MGMT (n = 70) | Unmethylated MGMT (n = 67) | Unknown MGMT (n = 30) | p valuea |
|---|---|---|---|---|---|
| Age at index | |||||
| Age, mean (SD) | 57 (12.4) | 60 (10.9) | 56 (12.8) | 55 (14.4) | 0.09d |
| Age ≥ 65 years, n (%) | 42 (31) | 21 (30) | 21 (31) | 8 (27) | 0.87b |
| Male, n (%) | 103 (62) | 40 (57) | 46 (69) | 17 (57) | 0.16b |
| Race, n (%) | 0.73c | ||||
| American Indian or Alaska Native | 2 (1) | 1 (1) | 1 (1) | 0 (0) | |
| Asian | 1 (1) | 0 (0) | 0 (0) | 1 (3) | |
| Black | 8 (5) | 2 (3) | 5 (7) | 1 (3) | |
| White | 146 (87) | 63 (90) | 57 (85) | 26 (87) | |
| Hispanic | 6 (4) | 2 (3) | 3 (4) | 1 (3) | |
| Other | 4 (2) | 1 (1) | 2 (3) | 1 (3) | |
| Location of lesion, n (%) | 0.23b | ||||
| Right side, frontal | 30 (18) | 9 (13) | 18 (27) | 3 (10) | |
| Left side, frontal | 26 (16) | 7 (10) | 12 (18) | 7 (23) | |
| Right side, parietal | 15 (9) | 8 (11) | 5 (7) | 2 (7) | |
| Left side, parietal | 14 (8) | 7 (10) | 5 (7) | 2 (7) | |
| Right side, temporal | 27 (16) | 17 (24) | 9 (13) | 1 (3) | |
| Left side, temporal | 18 (11) | 8 (11) | 7 (10) | 3 (10) | |
| Other | 37 (22) | 14 (20) | 11 (16) | 12 (40) | |
| Karnofsky performance status score at baseline, n (%) | 0.36c | ||||
| 100 | 12 (7) | 2 (3) | 9 (13) | 1 (3) | |
| 90 | 50 (30) | 22 (31) | 20 (30) | 8 (27) | |
| 80 | 38 (23) | 15 (21) | 13 (19) | 10 (33) | |
| 70 | 12 (7) | 5 (7) | 5 (7) | 2 (7) | |
| ≤ 60 | 5 (3) | 1 (1) | 1 (1) | 3 (10) | |
| Unknown | 49 (30) | 25 (36) | 19 (28) | 6 (20) | |
| Genomic alterations, n (%)e | |||||
| IDH1 | 23 (14) | 13 (19) | 5 (7) | 5 (17) | 0.05b |
| Charlson Comorbidity Index score at time of diagnosis, mean (SD) | 0.94 (2.1) | 0.99 (2.1) | 0.78 (2.1) | 1.2 (2.5) | 0.56d |
| Multifocal, n (%) | 16 (10) | 6 (9) | 6 (9) | 4 (13) | 0.94b |
| Other cancer, n (%)f | 34 (20) | 16 (23) | 11 (16) | 7 (23) | 0.34b |
| Family history of brain cancer or other cancers, n (%) | 0.98b | ||||
| Yes | 71 (43) | 26 (37) | 26 (39) | 19 (63) | |
| No | 64 (38) | 30 (43) | 28 (42) | 6 (20) | |
| Unknown | 32 (19) | 14 (20) | 13 (19) | 5 (17) | |
MGMT O6-methylguanine-DNA methyltransferase promoter, mMGMT methylated MGMT, uMGMT unmethylated MGMT, SD standard deviation
amMGMT vs uMGMT. bChi square test. cFisher’s exact test. dStudent’s t test. eOther genomic alterations were evaluated but did not show any significant differences. These included BRAF, EGFR, EGFR VIII, PDGFR, TERT, TERT and IDH1, and other. fOther cancers included any other malignancy, solid tumor, or blood malignancy that the patient had previously or at time of the survey completion, which were not glioblastoma